CanSino Biologics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CanSino Biologics Inc. - overview
Established
2009
Location
Tianjin, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2009 and based in Tianjin, China, CanSino Biologics Inc. operates as a biotechnology company that provides solutions to prevent communicable and infectious diseases. In 2012, the company completed the construction of a pilot plant designed to meet GMP standards. In 2018, it completed construction of a commercial production center.
In 2019, the company was listed on the Hong Kong Stock Exchange. Its stock code is 6185. In 2020, CanSino Biologics Inc. was listed on the Shanghai Stock Exchange.
Its stock code is 688185. The firm has vaccine industry bases in Tianjin and Shanghai, with a construction area of over 200,000 square meters. The company's main products include the new coronavirus vaccine (type 5 adenovirus vector) Keweisha®, the new crown vaccine Kewisha® Wuyou®, the quadrivalent meningococcal conjugate vaccine ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) Mann Haixin® and bivalent meningococcal conjugate vaccine group A and group C meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Minasi®, etc. Its products are used in diseases such as COVID-19, Ebola virus disease, tuberculosis, meningitis, and diphtheria.
Current Investors
Qiming Venture Partners, Lilly Asia Ventures, CITIC Goldstone Fund Management
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.cansinotech.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.